Abstract
A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
| Original language | English |
|---|---|
| Pages (from-to) | 266-268 |
| Number of pages | 3 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 65 |
| Issue number | 2 |
| Publication status | Published - 1998 |
Keywords
- Autoimmunity
- Cytokines
- Fucidin
- Guillian-Barre syndrome
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology
- Neuroscience(all)
- Psychiatry and Mental health
Fingerprint Dive into the research topics of 'Sodium fusidate in Gillain-Barre syndrome: A case report'. Together they form a unique fingerprint.
Cite this
Nicoletti, F., Nicoletti, A., Giuffrida, S., Di Marco, R., Meroni, P. L., Bendtzen, K., & Lunetta, M. (1998). Sodium fusidate in Gillain-Barre syndrome: A case report. Journal of Neurology, Neurosurgery and Psychiatry, 65(2), 266-268.